NasdaqGM - Nasdaq Real Time Price USD

Pomdoctor Limited (POM)

1.5650 +0.0150 (+0.97%)

As of 11:39:00 AM EST. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

POMDOCTOR LIMITED Regains Compliance with Nasdaq Bid Price Requirement

PR Newswire 3d ago

POM
+0.97%
^IXIC
POMDOCTOR LIMITED Advances Strategic Evolution from Traffic Monetization to Value-Based Healthcare Payment

PR Newswire 6d ago

POM
+0.97%
POMDOCTOR LIMITED Announces Receipt of Nasdaq Notifications Regarding Continued Listing Requirements

PR Newswire 7d ago

POM
+0.97%
^IXIC
POMDOCTOR LIMITED Announces the Termination of Its ADR Program and Trade Class A Ordinary Shares on Nasdaq

PR Newswire 22d ago

POM
+0.97%
POMDOCTOR LIMITED Highlights the Shift from Reactive Treatment to Predictive Healthcare

PR Newswire 29d ago

POM
+0.97%
POMDOCTOR LIMITED Announces Receipt of Nasdaq Staff Delisting Determination

PR Newswire 1mo ago

POM
+0.97%
POMDOCTOR LIMITED Accelerates AI-Enabled Chronic Disease Management and RWD Commercialization

PR Newswire 1mo ago

POM
+0.97%
POMDOCTOR LIMITED Highlights Differentiated "Hardware + AI + Payment" Healthcare Infrastructure Model

PR Newswire 1mo ago

POM
+0.97%
POMDOCTOR LIMITED to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

PR Newswire 1mo ago

POM
+0.97%
POMDOCTOR LIMITED Initiates U.S. Market Preparation and Unveils Expansion Strategy

PR Newswire 2mo ago

POM
+0.97%
POMDOCTOR LIMITED Highlights Healthcare Intelligence Flywheel as a Self-Reinforcing Growth Engine

PR Newswire 2mo ago

POM
+0.97%
POMDOCTOR LIMITED Advances Healthcare Data Asset Strategy to Strengthen AI-Powered Chronic Disease Management Capabilities

PR Newswire 3mo ago

POM
+0.97%

Performance Overview

Return	POM	S&P 500 (^GSPC)
YTD	-70.98%	+10.08%
1-Year	-98.41%	+10.29%
3-Year	-98.10%	+70.67%

U.S. markets close in 4h 3m

Pomdoctor Limited (POM)

POMDOCTOR LIMITED Regains Compliance with Nasdaq Bid Price Requirement

POMDOCTOR LIMITED Advances Strategic Evolution from Traffic Monetization to Value-Based Healthcare Payment

POMDOCTOR LIMITED Announces Receipt of Nasdaq Notifications Regarding Continued Listing Requirements

POMDOCTOR LIMITED Announces the Termination of Its ADR Program and Trade Class A Ordinary Shares on Nasdaq

POMDOCTOR LIMITED Highlights the Shift from Reactive Treatment to Predictive Healthcare

POMDOCTOR LIMITED Announces Receipt of Nasdaq Staff Delisting Determination

POMDOCTOR LIMITED Accelerates AI-Enabled Chronic Disease Management and RWD Commercialization

POMDOCTOR LIMITED Highlights Differentiated "Hardware + AI + Payment" Healthcare Infrastructure Model

POMDOCTOR LIMITED to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

POMDOCTOR LIMITED Initiates U.S. Market Preparation and Unveils Expansion Strategy

POMDOCTOR LIMITED Highlights Healthcare Intelligence Flywheel as a Self-Reinforcing Growth Engine

POMDOCTOR LIMITED Advances Healthcare Data Asset Strategy to Strengthen AI-Powered Chronic Disease Management Capabilities